From 2:15 to 3:05 PM on Tuesday, November 19, 2013, at the Hyatt Regency in Boston, Mr. Tassey will discuss how PAZ320 was recently found to exhibit Type 2 diabetes management efficacy in 45% of patients in an FDA Phase 2a clinical trial. PAZ320 is a non-systemic chewable tablet that lets patients manage their post-meal blood sugar levels, by targeting enzymes that digest sugar during digestion.
Mr. Tassey said, “TAP 2013 promises to be one of the key meetings of the year within the cardiovascular/metabolic disease area. We are pleased with this opportunity to educate attendees about the potential benefits of PAZ320, and are honored to be named a ‘Top Project to Watch’ by the independent panel.”
Since it was first started almost a decade ago, the conference has come to be one of the premier events in biopharmaceutical partnering. The event gathers the leading industry entrepreneurs and thought leaders to hear of the latest developments in biopharmaceuticals as well as provide quality networking opportunities. The “Top Projects to Watch” picks are determined by a panel of independent experts who screen hundreds of compounds and select the ones with the most potential as future products. Their criteria include: large market, large unmet need, with increasing opportunity; history of the molecule and drug; strong science; strong company; diversity of indications; potential for new opportunities beyond the initial indications; and multilevel partnering opportunities.
For more information, visit: www.bostonti.com
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment